Today on DrugResearcher.com   Merck's HIV vaccine steps out of development Sanofi imaging cancer drug 'sensors' Pfizer to spin off Japan drug research lab Three-way approach to personalised medicine 3D scaffold elevates drug screening results

Related Industry News   DSM takes on purification tech Bespak for sale? SolVin to increase PVDC production Novartis piling up approvals

Breaking News on Drug Discovery
Daily  Monday 24 September 2007		Forward to a colleague

	Company Profile CHIRALPAK® IC CHIRAL TECHNOLOGIES EUROPE announce the launch of CHIRALPAK® IC. The combination of CHIRALPAK® IA , IB and now IC provides a screening set of columns with exceptionally high success rates. The chiral separation of > 99% of all small molecules is attained using just 3 columns and four mobile phase combinations... Click Here Access Full Stories Merck's HIV vaccine steps out of development Merck & Co. has stopped the Phase II trial of its V520 HIV vaccine after interim results showed that the vaccine was not effective and did not prevent infection... Read Sanofi imaging cancer drug 'sensors' Sanofi-Aventis is using the latest targeted imaging techniques to assess how its cancer drugs affect organisms at the molecular level... Read Pfizer to spin off Japan drug research lab Pfizer is considering offers from investors in a bid to spin off its drug research and development laboratory in Japan and make it an independent entity, according to media reports... Read Three-way approach to personalised medicine UK antibody specialists Oxford Genome Science (OGeS) has signed new deals with Medarex and Biosite in order to help it produce personalised anticancer drugs faster... Read 3D scaffold elevates drug screening results UK researchers have developed a plastic cell scaffold that enables cells to be grown in realistic 3D  structures and promises to enable better cell based drug screening results... Read
	All News Headlines for: September | August | July
	Technical / White Paper DeltaDOT label free analysis of biomolecules Faster, higher quality results at a fraction of the cost of conventional approaches. Analyse & Quantify Antibodies, Proteins and Small molecules - with high resolution, sensitivity & reproducibility... Click Here
	Related Industry News DSM takes on purification tech Netherlands-based DSM has invested an undisclosed sum in Danish purification technology company Upfront Chromatography to boost its protein separation business... Read Bespak for sale? UK-based Bespak, one of the two contract manufacturers of Pfizer's inhaled insulin Exubera, confirmed on Friday it has been approached by a potential buyer... Read SolVin to increase PVDC production SolVin is to expand its polyvinylidene chloride (PVDC) latex manufacturing site in Tavaux, France, in a bid to meet growing demand for the packaging material... Read Novartis piling up approvals Novartis has announced its latest batch of thumbs up from EU regulators, potentially adding a few more products to its 'approved' list for this year... Read Weekly Comment Cheap drugs, no profit, just cures A group of leading drug developers have set up an international talent network for a 'global assault' on some of the world's deadliest diseases, such as tuberculosis (TB), malaria and AIDS, on a not-for-profit basis. Read Previous Headlines New US player in contract assay services field The burgeoning US contract assay services arena has witnessed the arrival of a brand new player with the launch of ReachBio, which is opening its business operations this week... Read Drugs moving into the clinic: 28 The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators... Read R&D news in brief DrugResearcher.com brings you a round up of the latest news in pharma research, including a busy week for the US Department of Defence, a terminated RNAi deal, a new type of influenza drug, and more... Read Preclinical services news in brief In this week's review of activity within the preclinical research services arena, new deals have emerged involving Alligator Bioscience, Indivumed, and Xceleron... Read Provectus' dye causes tumours to die Provectus has announced positive results for the first human trials of its new anticancer drug, which is based on a compound normally used as a dye... Read Product Innovation Alerts - Free of Charge Indicate your research interests and receive alerts on relevant products and market innovations Analysis and instrumentation Assays and screening Cell culture & Equipment Chromatography Compounds and consumables Contract services (outsourcing) Drug discovery Genomics / Proteomics Informatics & IT Lab equipment & consumables Liquid handling and automation Liquid handling and sample preparation Production technologies Separation and purification

	Free Newsletters for Pharmaceuticals Access now !Choose from over 20 industry e-newsletters Access Decision News Media e-newsletters for the food, beverage & nutrition industries, click here
	Forward to a colleague

	To continue to receive this newsletter in your inbox, please add newsletter@DrugResearcher.com to your address book
	Update preferences | Change your email address | Unsubscribe
	Contact us: Advertising | Recruitment | Privacy policy | Terms & conditions | Feedback
	© 2007 - Decision News Media S.A.S - All Rights Reserved Le Belem - 355, rue Vendemiaire - 34000 Montpellier - France http://www.decisionnewsmedia.com